Work

Emerging strategies to target RAS signaling in human cancer therapy

Year: 2021
Type: review
Abstract: RASmutations (HRAS,NRAS, andKRAS) are among the most common oncogenes, and around 19% of patients with cancer harborRASmutations. Cells harboringRASmutations tend to undergo malignant transformation and exhibit malignant phenotypes. The mutational status ofRAScorrelates with the clinicopathological features of patients, such as mucinous type and poor differentiation, as well as response to anti-EGFR therapies in certain types of human cancers. Although RAS protein had been considered as a potential target for tumors withRASmutations, it was once referred to as a undruggable target due to the consecutive failure in the discovery of RAS protein inhibitors. However, recent studies on the structure, signaling, and function of RAS have shed light on the development of RAS-targeting drugs, especially with the approval of Lumakras (sotorasib, AMG510) in treatment of KRASG12C-mutant NSCLC patients. Therefore, here we fully reviewRASmutations in human cancer and especially focus on emerging strategies that have been recently developed for RAS-targeting therapy.
Language: English
Open Access status: gold
Estimated APC paid: $3,990
OpenAlex ID: W3183860080
FWCI: 4.077
Cites: 229
Cited by: 272
Related to: 10